Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: Project ICARE phase 2

Clinical Infectious Diseases

Volumn 29, Issue 2, 1999, Pages 245-252

  Fridkin, Scott K ^a   Steward, Christine D ^a   Edwards, Jonathan R ^a   Pryor, Erica R ^a   McGowan Jr , John E ^a   Archibald, Lennox K ^a   Gaynes, Robert P ^a   Tenover, Fred C ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; AZTREONAM; CEFACLOR; CEFADROXIL; CEFALEXIN; CEFALOTIN; CEFAZOLIN; CEFMETAZOLE; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFTAZIDIME; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLOXACILLIN; DICLOXACILLIN; METICILLIN; MEZLOCILLIN; NAFCILLIN; OFLOXACIN; OXACILLIN; PENICILLIN DERIVATIVE; PENICILLIN G; PENICILLIN V; PIPERACILLIN; TICARCILLIN; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; CLINICAL LABORATORY; DISEASE TRANSMISSION; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; UNITED STATES;

EID: 0032813966     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/520193     Document Type: Article

References (20)

1. 1. Archibald L, Phillips L, McGowan JE Jr, Monnet D, Tenover FC, Gaynes RP. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: the increasing importance of the intensive care unit. Clin Infect Dis 1997;24:211-5.
2. 2. Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin United States, 1989-1993. MMWR Morb Mortal Wkly Rep 1993;42:597-9.
3. 3. Boyce JM. Are the epidemiology and microbiology of methicillin-resistant Staphylococcus aureus changing? JAMA 1998;279:623-4.
4. 4. Herold BC, Immergluck LC, Maranan MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998;279:593-8.
5. 5. Moreno F, Crisp C, Jorgensen JH, Patterson JE. Methicillin-resistant Staphylococcus aureus as a community organism. Clin Infect Dis 1995; 21:1308-12.
6. 6. Strausbaugh LJ, Crossley KB, Nurse BA, Thrupp LD. Antimicrobial resistance in long-term-care facilities. Infect Control Hosp Epidemiol 1996;17:129-40.
7. 7. Goldmann DA, Weinstein RA, Wenzel RP, et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. JAMA 1996;275:234-40.
8. 8. Monnet DL, Archibald LK, Phillips L, et al. Antimicrobial use and resistance in eight U.S. hospitals: complexities of analysis and modeling. Infect Control Hosp Epidemiol 1998;19:388-94.
9. 9. Emori G, Culver DH, Horan TC, et al. National Nosocomial Infections Surveillance (NNIS): description of surveillance methods. Am J Infect Control 1991;19:19-35.
10. 10. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. NCCLS document M7-A3. Villanova, PA: National Committee for Clinical Laboratory Standards, 1993.
11. 11. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests: approved standard. NCCLS document M2-A5. Villanova, PA: National Committee for Clinical Laboratory Standards, 1993.
12. 12. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: approved standard. NCCLS document M100-S6. Wayne, PA: National Committee for Clinical Laboratory Standards, 1995.
13. 13. Amsden GW, Schentag JJ. Tables of antimicrobial agent pharmacology. In: Mandell GL, Bennelt JE, Dolin R, eds. Principles and practice of infectious diseases. New York: Churchill Livingstone, 1995:492-528.
14. 14. Steward CD, McGowan JE Jr, Tenover FC, Fridkin SK, Gaynes RP. Multicenter study of susceptibility of imipenem demonstrates that testing problems persist [abstract no 769]. Clin Infect Dis 1998;27:1064.
15. 15. Hoiby N. Microbiology of cystic fibrosis. In: Hudsen ME, Geddes DM, eds. Cystic fibrosis. London: Chapman and Hall Medical, 1995;84.
16. 16. Kielhofner M, Atmar RL. Life-threatening Pseudomonas aeruginosa infections in patients with human immunodeficiency virus infection. Clin Infect Dis 1992;14:403-11.
17. 17. Pfaller MA, Jones RN, Marshall SA, Edmond MB, Wenzel RP, SCOPE Hospital Study Group. Nosocomial streptococcal blood stream infections in the SCOPE Program: species occurrence and antimicrobial resistance. Diagn Microbiol Infect Dis 1997;29:259-63.
18. 18. Fridkin SK, Pryor ER, Edwards JR, McGowan JE Jr, Tenover FC, Gaynes RP. Do hospital antibiograms reflect resistance in nosocomial infections? [abstract no 90]. In: Program and abstracts of the 8th annual meeting of the Society for Healthcare Epidemiology of America (Woodbury, NJ). 1998:40.
19. 19. White RL, Kays MB, Friedrich LV, Brown EW, Koonce JR. Pseudoresistance of Pseudomonas aeruginosa resulting from degradation of imipenem in an automated susceptibility testing system with predried panels. J Clin Microbiol 1991;29:398-400.
20. 20. Sartor C, Edwards JR, Gaynes RP, Culver DH. Evolution of hospital participation in the National Nosocomial Infections Surveillance System, 1986 to 1993. Am J Infect Control 1995;23:364-8.